7,400,000 Shares in Certara, Inc. $CERT Acquired by Haveli Investment Management LLC

Haveli Investment Management LLC acquired a new stake in Certara, Inc. (NASDAQ:CERT) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 7,400,000 shares of the company’s stock, valued at approximately $48,470,000,000. Certara accounts for 26.9% of Haveli Investment Management LLC’s holdings, making the stock its 2nd largest holding.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. grew its holdings in Certara by 2,733.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after acquiring an additional 2,870 shares during the period. Osaic Holdings Inc. lifted its stake in shares of Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Certara by 499.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after purchasing an additional 4,930 shares during the period. State of Wyoming bought a new position in shares of Certara in the 2nd quarter worth $72,000. Finally, Pacer Advisors Inc. grew its stake in shares of Certara by 28.1% during the first quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock worth $75,000 after purchasing an additional 2,871 shares during the period. 73.96% of the stock is owned by institutional investors.

Certara Price Performance

Shares of NASDAQ CERT opened at $8.14 on Wednesday. The company has a fifty day moving average price of $7.21 and a 200 day moving average price of $6.45. The firm has a market cap of $1.24 billion, a PE ratio of -18.09 and a beta of 1.44. The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.30. Certara, Inc. has a 1-year low of $4.45 and a 1-year high of $13.88.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $93.27 million during the quarter, compared to the consensus estimate of $98.09 million. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The business’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.07 earnings per share. Research analysts predict that Certara, Inc. will post 0.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CERT has been the topic of a number of analyst reports. Barclays increased their price target on shares of Certara from $6.50 to $7.50 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. Craig Hallum decreased their target price on Certara from $10.00 to $8.00 and set a “hold” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings upgraded Certara from a “sell (e+)” rating to a “sell (d)” rating in a report on Wednesday, August 5th. Stephens cut their price objective on Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Finally, BMO Capital Markets cut their price objective on Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $8.28.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.